[{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Betaine","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cosette Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"The Queen's University of Belfast","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Infusion","sponsorNew":"PharmaTher \/ The Queen's University of Belfast","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ The Queen's University of Belfast"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Betaine","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Betaine","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Undisclosed \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Eton Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Betaine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Betaine anhydrous for oral solution is indicated in children and adults for the treatment of homocystinuria to decrease high homocysteine blood levels. The program will provide prescription fulfillment, insurance benefits investigation, educational suppo...

                          Product Name : Cystadane-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 05, 2023

                          Lead Product(s) : Betaine

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Cystadane (betaine anhydrous) transfers a methyl group via the enzyme betaine homocysteine methyl transferase, converting homocysteine back into methionine and dimethylglycine. In patients with homocystinuria, betaine reduces homocysteine levels and impr...

                          Product Name : Cystadane

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 03, 2023

                          Lead Product(s) : Betaine

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Undisclosed

                          Country arrow
                          MAGHREB PHARMA
                          Not Confirmed

                          Undisclosed

                          Country arrow
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Betaine shares the same prescriber base as the carglumic acid tablets, so it is an attractive opportunity to leverage the existing commercial infrastructure.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 13, 2022

                          Lead Product(s) : Betaine

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Eton Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : KETABET (Ketamine and Betaine) aims to prevent the potential adverse psychiatric effects of repeated ketamine treatment for depression and other indications, including suicidal ideation, substance abuse, post-traumatic stress disorder, and chronic pain.

                          Product Name : Ketabet

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 06, 2022

                          Lead Product(s) : Ketamine Hydrochloride,Betaine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Company’s patented hydrogel-forming microneedle patch, PHARMAPATCH™, to deliver ketamine and KETABET™ (ketamine and betaine anhydrous), which aims to prevent the potential side effects of repeated ketamine treatment for depression and other indicat...

                          Product Name : Ketabet

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          June 29, 2022

                          Lead Product(s) : Ketamine Hydrochloride,Betaine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : KETABET™, a patented combination formulation of FDA-approved ketamine and betaine anhydrous, has been shown in research to enhance the antidepressant effect while having the potential to reduce the known negative side effects of ketamine significantly.

                          Product Name : Ketabet

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          June 15, 2021

                          Lead Product(s) : Ketamine Hydrochloride,Betaine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : The proposed ketamine and KETABET™ MN patch offer a potential game-changing therapeutic solution for various unmet medical needs.

                          Product Name : Ketabet

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          March 24, 2021

                          Lead Product(s) : Ketamine Hydrochloride,Betaine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : The Queen's University of Belfast

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank